Portal de Periódicos da CAPES

Bridge to Transplantation: Current Outcomes

2010; Wiley; Volume: 25; Issue: 4 Linguagem: Inglês

10.1111/j.1540-8191.2010.00996.x

1540-8191

Sanjeev Aggarwal, Francis D. Pagani,

Transplantation: Methods and Outcomes

Journal of Cardiac SurgeryVolume 25, Issue 4 p. 455-461 Bridge to Transplantation: Current Outcomes Sanjeev Aggarwal M.D., Sanjeev Aggarwal M.D. Division of Thoracic and Cardiovascular Surgery, University of Louisville, Louisville, Kentucky and Section of Cardiac Surgery, University of Michigan Health System, Ann Arbor, MichiganSearch for more papers by this authorFrancis D. Pagani M.D., PhD., Francis D. Pagani M.D., PhD. Division of Thoracic and Cardiovascular Surgery, University of Louisville, Louisville, Kentucky and Section of Cardiac Surgery, University of Michigan Health System, Ann Arbor, MichiganSearch for more papers by this author Sanjeev Aggarwal M.D., Sanjeev Aggarwal M.D. Division of Thoracic and Cardiovascular Surgery, University of Louisville, Louisville, Kentucky and Section of Cardiac Surgery, University of Michigan Health System, Ann Arbor, MichiganSearch for more papers by this authorFrancis D. Pagani M.D., PhD., Francis D. Pagani M.D., PhD. Division of Thoracic and Cardiovascular Surgery, University of Louisville, Louisville, Kentucky and Section of Cardiac Surgery, University of Michigan Health System, Ann Arbor, MichiganSearch for more papers by this author First published: 01 July 2010 https://doi.org/10.1111/j.1540-8191.2010.00996.xCitations: 19 Address for correspondence: Francis D. Pagani, M.D., PhD., Otto Gago, M.D., Professor of Surgery, Section of Cardiac Surgery, University of Michigan Health System, Cardiovascular Center–Room 5161, 1500 East Medical Center Drive, SPC 5864, Ann Arbor, MI 48109-5864. Tel: 734-647-2894; e-mail: [email protected] Disclosures: Dr. Pagani is a principal site investigator for clinical trials evaluating the HeartMate II (Thoratec Corporation), DuraHeart (Terumo Cardiovascular Corporation), and HVAD (HeartWare Corporation) devices. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Abstract Abstract The use of implantable ventricular assist devices for the treatment of advanced, decompensated heart failure as a bridge to heart transplantation has experienced considerable evolution over the past decade. Improvements in the management and prevention of serious adverse events, and introduction of new continuous-flow rotary pumps that are smaller, more durable, and associated with fewer serious adverse advents has expanded the use of this therapy to a larger population of patients for bridge to transplant indication. (J Card Surg 2010;25:455-461) REFERENCES 1 Mulligan MS, Shearon TH, Weill D, et al: Heart and lung transplantation in the United States, 1997–2006. Am J Transplant 2008; 8: 977- 987. 2 Frazier O, Rose E, Macmanus Q, et al: Multicenter clinical evaluation of the Heart Mate 1000 IP left ventricular assist device. Ann Thorac Surg 1992; 53: 1080- 1090. 3 Frazier OH, Rose EA, Oz MC, et al: Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg 2001; 122: 1186- 1195. 4 Slaughter MS, Tsui SS, El-Banayosy A, et al: Results of a multicenter clinical trial with the thoratec implantable ventricular assist device. J Thorac Cardiovasc Surg 2007; 133: 1573- 1580. 5 Joyce LD, Noon GP, Joyce DL, et al: Mechanical circulatory support–a historical review. ASAIO J 2004; 50: x– xii. 6 Portner PM, Oyer PE, McGregor CGA, et al: First human use of an electrically-powered implantable ventricular assist system. Artif Organs 1985; 9: 36.[Abstract] 7 Dagenais F, Portner PM, Robbins RC, Oyer PE: The Novacor left ventricular assist system: Clinical experience from the Novacor registry. J Card Surg 2001; 16: 267- 271. 8 Deng MC, Loebe M, El-Banayosy A, et al: Mechanical circulatory support for advanced heart failure: Effect of patient selection on outcome. Circulation 2001; 103: 231- 237. 9 Baughman KL, Jarcho JA: Bridge to life–cardiac mechanical support. N Engl J Med 2007; 357: 846- 849. 10 Jaski BE, Lingle RJ, Kim J, et al: Comparison of functional capacity in patients with end-stage heart failure following implantation of a left ventricular assist device versus heart transplantation: results of the experience with left ventricular assist device with exercise trial. J Heart Lung Transplant 1999; 18: 1031- 1040. 11 De Jonge N, Kirkels H, Lahpor JR, et al: Exercise performance in patients with end-stage heart failure after implantation of a left ventricular assist device and after heart transplantation: an outlook for permanent assisting? J Am Coll Cardiol 2001; 37: 1794- 1799. 12 Haft J, Armstrong W, Dyke DB, et al: Hemodynamic and exercise performance with pulsatile and continuous flow left ventricular assist devices. Circulation 2007; 116(Suppl I): I8- I15. 13 Young JB: Healing the heart with ventricular assist device therapy: Mechanisms of cardiac recovery. Ann Thorac Surg 2001; 71: S210- S219. 14 Burkhoff D, Klotz S, Mancini D: LVAD-induced reverse remodeling: Basic and clinical implications for myocardial recovery. J Card Failure 2006; 12: 227- 239. 15 Dembitsky WP, Tector AJ, Park S, et al: Left ventricular assist device performance with long term circulatory support: Lessons from the REMATCH trial. Ann Thorac Surg 2004; 78: 2123- 2130. 16 Pagani FD, Long JW, Dembitsky WP, et al: Improved mechanical reliability of the HeartMate XVE left ventricular assist system. Ann Thorac Surg 2006; 82: 1413- 1419. 17 Miller LW, Pagani FD, Russell SD, et al: Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 2007; 357: 885- 896. 18 Pagani FD, Miller LW, Russell SD, et al: Extended mechanical circulatory support with a continuous-flow left ventricular assist device. J Am Coll Cardiol 2009; 54: 312- 321. 19 Goldstein DJ, Zucker M, Arroyo L, et al: Safety and feasibility trial of the MicroMed DeBakey ventricular assist device as a bridge to transplantation. J Am Coll Cardiol 2005; 45: 962- 963. 20 Frazier OH, Myers TJ, Jarvik RK, et al: Research and development of an implantable, axial-flow left ventricular assist device: the Jarvik 2000 heart. Ann Thorac Surg 2001; 71(Suppl 1): S125- S132. 21 Siegenthaler MP, Frazier OH, Beyersdorf F, et al: Mechanical reliability of the Jarvik 2000 Heart. Ann Thorac Surg 2006; 81: 1752- 1758. 22 Aaronson KD, Eppinger M, Dyke BD, et al: LVAD therapy improves utilization of donor hearts. J Am Coll Cardiol 2002; 39: 1247- 1254. 23 Massad MG, McCarthy PM, Smedira NG, et al: Does successful bridging with the implantable left ventricular assist device affect cardiac transplantation outcome? J Thorac Cardiovasc Surg 1996; 112: 1275- 1283. 24 Taylor DO, Edwards LB, Boucek MM, et al: Registry of the International Society for Heart and Lung Transplantation: Twenty-third Official Adult Heart Transplantation Report–2006. J Heart Lung Transplant 2006; 25: 869- 879. 25 Cleveland JC, Grover FL, Fullerton DA, et al: Left ventricular assist device as bridge to transplantation does not adversely affect one-year heart transplantation survival. J Thorac Cardiovasc Surg 2008; 136: 774- 777. 26 Patlolla V, Patten RD, DeNofrio D, et al: The effect of ventricular assist devices on post-transplant mortality: An analysis of the United Network for Organ Sharing Thoracic Registry. J Am Coll Cardiol 2009; 53: 264- 271. 27 Holman WL, Kormos RL, Naftel DC, et al: Predictors of death and transplant in patients with a mechanical circulatory support device: A multi-institutional study. J Heart Lung Transplant 2009; 28: 44- 50. 28 Kirklin JK, Naftel DC, Stevenson LW, et al: INTERMACS Database for durable devices for circulatory support: First annual report. J Heart Lung Transplant 2008; 27: 1065- 1072. 29 Jahanyar J, Noon GP, Koerner MM, et al: Recurrent device thrombi during mechanical circulatory support with an axial-flow pump is a treatable condition and does not preclude successful long-term support. J Heart Lung Transplant 2007; 26: 200- 203. 30 Takatani S: Progress of rotary blood pumps: Presidential Address, International Society for Rotary Blood Pumps 2006, Leuven, Belgium. Artif Organs 2007; 31: 329- 344. 31 Nishinaka T, Schima H, Roethy W, et al: The DuraHeart VAD, a magnetically levitated centrifugal pump. The University of Vienna bridge to transplant experience. Circ J 2006; 70: 1421- 1425. 32 Nojiri C, Fey O, Jaschke F, et al: Long-term circulatory support with the DuraHeart mag-lev centrifugal left ventricular assist system for advanced heart failure patients eligible to transplantation: European experiences. J Heart Lung Transplant 2008; 27: S245.[Abstract] 33 Tuzun E, Roberts K, Cohn WE, et al: In vivo evaluation of the HeartWare centrifugal ventricular assist device. Texas Heart Inst J 2007; 34: 406- 411. 34 Wieselthaler GM, Strueber M, O′Driscoll GA, et al: Experience with the novel HeartWare HVAD with hydromagnetically levitated rotor in a multi-institutional trial. J Heart Lung Transplant 2008; 27: S245.[Abstract] Citing Literature Volume25, Issue4July 2010Pages 455-461 ReferencesRelatedInformation